锦欣生殖(01951)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

01951 锦欣生殖

已收盘 04-25 16:09:09

2.460

-0.020

-0.81%

最高2.530	最低2.440	成交量1,410万
今开2.490	昨收2.480	日振幅3.63%
总市值67.84亿	流通市值67.84亿	总股本27.58亿
成交额3,494万	换手率0.51%	流通股本27.58亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"01951","market":"HK","secType":"STK","nameCN":"锦欣生殖","latestPrice":2.46,"timestamp":1714032549013,"preClose":2.48,"halted":0,"volume":14101000,"delay":0,"floatShares":2757706043,"shares":2757706043,"eps":0.13883694,"marketStatus":"已收盘","marketStatusCode":5,"change":-0.02,"latestTime":"04-25 16:09:09","open":2.49,"high":2.53,"low":2.44,"amount":34939260,"amplitude":0.03629,"askPrice":2.46,"askSize":41500,"bidPrice":2.45,"bidSize":143500,"shortable":3,"etf":0,"ttmEps":0.13204376447374602,"exchange":"SEHK","tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1714095000000},"adr":0,"listingDate":1561392000000,"adjPreClose":2.48,"dividendRate":0.023642,"openAndCloseTimeList":[[1714008600000,1714017600000],[1714021200000,1714032000000]],"volumeRatio":1.816263,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/01951","defaultTab":"news","newsList":[{"id":"2429115039","title":"锦欣生殖04月23日获主力加仓414万元 环比增加885.71%","url":"https://stock-news.laohu8.com/highlight/detail?id=2429115039","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2429115039?lang=zh_cn&edition=full","pubTime":"2024-04-23 16:15","pubTimestamp":1713860152,"startTime":"0","endTime":"0","summary":"04月23日, 锦欣生殖股价涨3.45%，报收2.40元，成交金额2282万元，换手率0.35%，振幅4.31%，量比1.29。锦欣生殖今日主力资金净流入414万元，上一交易日主力净流入42万元，今日环比增加885.71%。该股近5个交易日上涨6.19%，主力资金累计净流入272万元；近20日主力资金累计净流出849万元，其中净流出天数为12日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024042316161887a53155&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024042316161887a53155&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2429473150","title":"共筑医疗温情新篇章｜锦欣生殖集团2024年度优质服务第一期培训圆满举行","url":"https://stock-news.laohu8.com/highlight/detail?id=2429473150","media":"JXR锦欣生殖","top":-1,"share":"https://www.laohu8.com/m/news/2429473150?lang=zh_cn&edition=full","pubTime":"2024-04-23 09:00","pubTimestamp":1713834000,"startTime":"0","endTime":"0","summary":"2024年4月18日下午，在四川锦欣西囡妇女儿童医院成功举办了2024年首期优质服务培训，旨在提升全员服务意识，优化患者体验。锦欣生殖集团将继续秉承以病人为中心的服务理念，不断追求卓越，致力于为每一位患者提供更加温馨、专业的医疗服务。锦欣生殖以辅助生殖业务为核心，积极拓展生育全周期的产品和服务，致力于为患者提供最优质的生育一体化服务，并助力国家人口健康发展。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://mp.weixin.qq.com/s?__biz=MzUwOTg5MDE0NA==&mid=2247495235&idx=4&sn=8e692b74d765fab454c1b5c67b25f622&chksm=f909f54cce7e7c5a261921a27540e98c1af02a9ff6344fca18600a15a2512581d59650376793#rd","is_publish_highlight":false,"gpt_icon":0},{"id":"2429150406","title":"健嘉医疗和南昌市生殖医院相关领导莅临四川锦欣西囡妇女儿童医院参观交流学习","url":"https://stock-news.laohu8.com/highlight/detail?id=2429150406","media":"JXR锦欣生殖","top":-1,"share":"https://www.laohu8.com/m/news/2429150406?lang=zh_cn&edition=full","pubTime":"2024-04-23 09:00","pubTimestamp":1713834000,"startTime":"0","endTime":"0","summary":"4月16至17日，健嘉医疗副总经理华崇先生和南昌市生殖医院相关院领导一行5人，来到锦欣生殖集团旗下四川锦欣西囡妇女儿童医院进行了为期两天的参访交流学习活动。参访嘉宾们首先来到了四川锦欣西囡妇女儿童医院，对院区的现场环境和各楼层服务功能布局，做了详细了解。此次健嘉集团和南昌市生殖医院相关嘉宾来蓉的参访交流学习活动，在热烈而富有成效的氛围中圆满落幕。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://mp.weixin.qq.com/s?__biz=MzUwOTg5MDE0NA==&mid=2247495235&idx=3&sn=28d6c3b37bd622f3ca8e3493f5273f55&chksm=f909f54cce7e7c5a6220ed9a2194611200f181c5fef1df0b1ce986762358d8390d92cad2e01e#rd","is_publish_highlight":false,"gpt_icon":0},{"id":"2428806395","title":"锦欣生殖04月17日主力资金流出187万元 连续3日减仓","url":"https://stock-news.laohu8.com/highlight/detail?id=2428806395","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2428806395?lang=zh_cn&edition=full","pubTime":"2024-04-17 16:17","pubTimestamp":1713341821,"startTime":"0","endTime":"0","summary":"04月17日, 锦欣生殖股价涨1.77%，报收2.30元，成交金额1730万元，换手率0.27%，振幅3.10%，量比0.71。锦欣生殖今日主力资金净流出187万元，连续3日净流出，上一交易日主力净流出271万元，今日环比减少31.00%。近一年数据显示，该股主力连续3日净流出后，次日下跌概率为66.67%，平均跌幅为1.58%。该股近5个交易日下跌10.89%，主力资金累计净流出670万元，其中1个交易日为股价上涨时净流出；近20日主力资金累计净流出1081万元，其中净流出天数为12日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404171617338b2df8ae&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404171617338b2df8ae&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2426276720","title":"中邮证券：内生增长稳健 港股保健护理服务板块估值具备较强吸引力","url":"https://stock-news.laohu8.com/highlight/detail?id=2426276720","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2426276720?lang=zh_cn&edition=full","pubTime":"2024-04-12 15:07","pubTimestamp":1712905646,"startTime":"0","endTime":"0","summary":"结合成长性来看，中国香港保健护理服务板块整体成长增速明显高于美国和日本。基于以上，中国香港保健护理服务板块估值具备较强的吸引力。中邮证券主要观点如下：港股医疗服务标的业绩大部分实现稳健增长从港股医疗服务标的整体业绩表现来看，除了ICL由于新冠前期收入高基数，口腔受种植牙集采影响收入皆有下降外，其他医疗服务标的收入大部分有较好增长。辅助生殖周期数保持快速增长，单周期价格稳健提升。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1101600.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2426900552","title":"【港股通】锦欣生殖(01951)涨5.76% 花旗指其估值仍然具有吸引力","url":"https://stock-news.laohu8.com/highlight/detail?id=2426900552","media":"金吾财讯","top":-1,"share":"https://www.laohu8.com/m/news/2426900552?lang=zh_cn&edition=full","pubTime":"2024-04-09 10:30","pubTimestamp":1712629812,"startTime":"0","endTime":"0","summary":"金吾财讯 | 锦欣生殖 早盘股价震荡上扬，截至发稿，涨5.76%，报2.57港元。消息面上，4月1日，锦欣生殖医疗集团有限公司宣布与印尼PT Morula Indonesia签署股权投资协议。锦欣生殖称，投资完成后，锦欣生殖将成为Morula最大的战略投资人。花旗发布研究报告称，维持锦欣生殖“买入”评级，考虑到深圳新院区延迟开业及武汉医院的利润，将2024及2025年收入下调10%和16.8%，每股盈测下调37.7%及40.9%，目标价由11.5港元下调至6港元。该行认为其估值仍然具有吸引力。","market":"fut","thumbnail":"https://static.szfiu.com/news/20210810/NjUzMWVjZjQ5MDRjNGY2OWIzOTk1NmJhNzg4ZTIwMmI4MTQyOTUwMDc1MDA=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210810/NjUzMWVjZjQ5MDRjNGY2OWIzOTk1NmJhNzg4ZTIwMmI4MTQyOTUwMDc1MDA=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"1934660","is_publish_highlight":false,"gpt_icon":0},{"id":"2426745907","title":"港股异动 | 锦欣生殖(01951)涨超6% 多地辅助生殖纳入医保 公司拓展东南亚辅助生殖市场","url":"https://stock-news.laohu8.com/highlight/detail?id=2426745907","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2426745907?lang=zh_cn&edition=full","pubTime":"2024-04-09 10:29","pubTimestamp":1712629753,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，锦欣生殖涨超6%，截至发稿，涨6.17%，报2.58港元，成交额2936.65万港元。消息面上，4月1日起，山东辅助生殖类医疗服务项目正式纳入医保。此外，据国家医保局日前消息，北京、广西、内蒙古、甘肃四省份已先后将辅助生殖纳入医保报销。投资完成后，锦欣生殖将成为Morula最大的战略投资人。同时，双方将达成战略合作，实现资源整合，携手开拓印尼及东南亚辅助生殖行业市场。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1099798.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2426390205","title":"锦欣生殖(01951)上涨5.35%，报2.56元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2426390205","media":"金融界","top":-1,"share":"https://www.laohu8.com/m/news/2426390205?lang=zh_cn&edition=full","pubTime":"2024-04-09 10:14","pubTimestamp":1712628850,"startTime":"0","endTime":"0","summary":"4月9日，锦欣生殖(01951)盘中上涨5.35%，截至10:14，报2.56元/股，成交1806.45万元。锦欣生殖医疗集团有限公司是中美领先的辅助生殖服务机构，拥有和经营多家医院和医疗中心，主要提供辅助生殖服务及相关治疗。根据弗若斯特沙利文报告，2018年，公司在中国辅助生殖服务市场中排名第三，进行了20,958个体外受精取卵周期，市场份额约为3.1%，在非国有辅助生殖服务机构中排名第一。截至2023年年报，锦欣生殖营业总收入27.89亿元、净利润3.45亿元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2024/04/09101440160212.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2426188326","title":"锦欣生殖盘中异动 大幅拉升5.35%报2.561港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2426188326","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2426188326?lang=zh_cn&edition=full","pubTime":"2024-04-09 10:14","pubTimestamp":1712628848,"startTime":"0","endTime":"0","summary":"2024年04月09日早盘10时14分，锦欣生殖股票出现异动，股价急速上涨5.35%。截至发稿，该股报2.561港元/股，成交量711.1万股，换手率0.26%，振幅5.35%。锦欣生殖股票所在的生物技术行业中，整体跌幅为0.40%。其相关个股中，宜明昂科-B、康希诺生物、锦欣生殖涨幅较大，振幅较大的相关个股有百奥赛图-B、宜明昂科-B、科笛-B，振幅分别为12.17%、10.85%、9.80%。管理服务部门向锦江生殖中心及锦欣生育中心提供共同管理服务。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024040910140987e7eb6a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024040910140987e7eb6a&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2426907285","title":"锦欣生殖(01951)股价上升5.35%，现价港币$2.56","url":"https://stock-news.laohu8.com/highlight/detail?id=2426907285","media":"阿斯达克财经","top":-1,"share":"https://www.laohu8.com/m/news/2426907285?lang=zh_cn&edition=full","pubTime":"2024-04-09 10:14","pubTimestamp":1712628840,"startTime":"0","endTime":"0","summary":"[上升股]锦欣生殖(01951) 股价在上午10:14比前收市价上升5.35%，现股价为港币$2.56。至目前为止，今日最高价为$2.56，而最低价为$2.43。总成交量为711.1万股，总成交金额为港币$1.782千万。","market":"hk","thumbnail":"http://plib.aastocks.com/aafnnews/image/medialib/20180112133337750_s.jpg","type":0,"news_type":0,"thumbnails":["http://plib.aastocks.com/aafnnews/image/medialib/20180112133337750_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAR2404091251/aamm-all-category","is_publish_highlight":false,"gpt_icon":0},{"id":"2426490774","title":"对标学习拓思路，交流借鉴促提升｜生殖质控部组织集团内部交流学习活动","url":"https://stock-news.laohu8.com/highlight/detail?id=2426490774","media":"JXR锦欣生殖","top":-1,"share":"https://www.laohu8.com/m/news/2426490774?lang=zh_cn&edition=full","pubTime":"2024-04-09 09:43","pubTimestamp":1712626980,"startTime":"0","endTime":"0","summary":"为加快医院发展需求，促进集团内医务人员的交流和学习，实现资源共享和能力提升。三月底，锦欣生殖质控部组织了两期集团医生实地参观交流学习活动。第二期活动为3月25日至27日，共3天。通过这两期培训，与会医生都表示收获良多，真正做到了集团各院区之间对标学习拓思路，交流借鉴促提升。锦欣生殖以辅助生殖业务为核心，积极拓展生育全周期的产品和服务，致力于为患者提供最优质的生育一体化服务，并助力国家人口健康发展。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://mp.weixin.qq.com/s?__biz=MzUwOTg5MDE0NA==&mid=2247495085&idx=4&sn=5a1677a7c5e0f697c285f90c03dd91a3&chksm=f909f6a2ce7e7fb4e0dc8ef9b9eb93829de71577779c47c1f82c73ccae3315f7d0a7827f4133#rd","is_publish_highlight":false,"gpt_icon":0},{"id":"2426449072","title":"理想予你，未来随欣｜锦欣生殖集团24年春季硕博专场","url":"https://stock-news.laohu8.com/highlight/detail?id=2426449072","media":"JXR锦欣生殖","top":-1,"share":"https://www.laohu8.com/m/news/2426449072?lang=zh_cn&edition=full","pubTime":"2024-04-09 09:43","pubTimestamp":1712626980,"startTime":"0","endTime":"0","summary":"长按关注 ｜更多一手资讯锦欣生殖 是专业的、具有全球影响力的辅助生殖和妇儿医疗服务提供商，旗下医疗机构分布在中国内地，香港，美国和东南亚地区。锦欣生殖以辅助生殖业务为核心，积极拓展生育全周期的产品和服务，致力于为患者提供最优质的生育一体化服务，并助力国家人口健康发展。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://mp.weixin.qq.com/s?__biz=MzUwOTg5MDE0NA==&mid=2247495085&idx=1&sn=ea9c816826fe500a9cd11c192b33d648&chksm=f909f6a2ce7e7fb4540c6e2c2bb7812d1ca4f5f717ecd756522fd922a0d3508541984e4a0bba#rd","is_publish_highlight":false,"gpt_icon":0},{"id":"2426449070","title":"三月新员工培训圆满落幕，共筑企业未来新篇章","url":"https://stock-news.laohu8.com/highlight/detail?id=2426449070","media":"JXR锦欣生殖","top":-1,"share":"https://www.laohu8.com/m/news/2426449070?lang=zh_cn&edition=full","pubTime":"2024-04-09 09:43","pubTimestamp":1712626980,"startTime":"0","endTime":"0","summary":"三月份在成都地区、云南地区组织了一次全面而系统的新员工入职培训。旨在通过系统的学习和实践，使新员工能够在加入锦欣后，第一时间快速融入，掌握基本的工作技能和方法，为未来的职业发展奠定坚实的基础。我们也期待新员工们能够充分发挥自己的潜力和才能，为公司的发展贡献自己的力量，共同书写企业未来的新篇章。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://mp.weixin.qq.com/s?__biz=MzUwOTg5MDE0NA==&mid=2247495085&idx=3&sn=38354ca2890922f0512afa3dfbf64ba0&chksm=f909f6a2ce7e7fb4584a242742982dad313720ca2dd604790ebb7f72333e9d795ab1ea3a6a76#rd","is_publish_highlight":false,"gpt_icon":0},{"id":"2426144907","title":"锦欣生殖与印尼Morula达成股权战略投资合作，拓展东南亚辅助生殖市场","url":"https://stock-news.laohu8.com/highlight/detail?id=2426144907","media":"JXR锦欣生殖","top":-1,"share":"https://www.laohu8.com/m/news/2426144907?lang=zh_cn&edition=full","pubTime":"2024-04-09 09:43","pubTimestamp":1712626980,"startTime":"0","endTime":"0","summary":"2024年4月1日，锦欣生殖医疗集团有限公司宣布与印尼PT Morula Indonesia签署股权投资协议。投资完成后，锦欣生殖将成为Morula最大的战略投资人。同时，双方将达成战略合作，实现资源整合，携手开拓印尼及东南亚辅助生殖行业市场。目前锦欣生殖旗下医疗机构分布在中国大陆、中国香港、美国以及东南亚地区。作为锦欣生殖的战略合作伙伴，Morula市场份额和成功率在过去均不断提升，也在印尼市场展现了持续增长的能力。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://mp.weixin.qq.com/s?__biz=MzUwOTg5MDE0NA==&mid=2247495085&idx=2&sn=78fdd7ab481fef7bb8f08d0fd54f181e&chksm=f909f6a2ce7e7fb4a1cc2f36561ab3b66d4962724038609e97ce47f37641173b4c511c7519ee#rd","is_publish_highlight":false,"gpt_icon":0},{"id":"2425660054","title":"锦欣生殖(01951)出现大手买入85.45万股，成交价$2.45，涉资209.353万","url":"https://stock-news.laohu8.com/highlight/detail?id=2425660054","media":"阿斯达克财经","top":-1,"share":"https://www.laohu8.com/m/news/2425660054?lang=zh_cn&edition=full","pubTime":"2024-04-08 10:10","pubTimestamp":1712542200,"startTime":"0","endTime":"0","summary":"[大手成交]锦欣生殖(01951)在上午10:10出现大手买入，成交量为85.45万，成交价为港币$2.45，涉资209.353万。至目前为止，股价升3.814%，今日最高价为$2.46，而最低价为$2.37，总成交量为629.7万股，总成交金额港币$1.532千万。","market":"fut","thumbnail":"http://plib.aastocks.com/aafnnews/image/medialib/20180205145550868_s.jpg","type":0,"news_type":0,"thumbnails":["http://plib.aastocks.com/aafnnews/image/medialib/20180205145550868_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAV2404082273/aamm-all-category","is_publish_highlight":false,"gpt_icon":0},{"id":"2425958243","title":"辅助生殖纳入医保，产业链公司站上“风口”！","url":"https://stock-news.laohu8.com/highlight/detail?id=2425958243","media":"财华社","top":-1,"share":"https://www.laohu8.com/m/news/2425958243?lang=zh_cn&edition=full","pubTime":"2024-04-05 14:51","pubTimestamp":1712299875,"startTime":"0","endTime":"0","summary":"辅助生殖再度迎来利好。近日，在国家医保局的指导下，北京、广西、内蒙古、甘肃4省份已将辅助生殖纳入医保报销。","market":"other","thumbnail":"https://images.finet.hk/photoLib/title/202404_1/3a0c27cd-acc3-46d3-8194-46b970526fea.png","type":0,"news_type":0,"thumbnails":["https://images.finet.hk/photoLib/title/202404_1/3a0c27cd-acc3-46d3-8194-46b970526fea.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.finet.hk/newscenter/news_content/660f9f63bde0b33a753dc80a","is_publish_highlight":false,"gpt_icon":0},{"id":"2425301397","title":"花旗：维持锦欣生殖(01951)“买入”评级 目标价下调至6港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2425301397","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2425301397?lang=zh_cn&edition=full","pubTime":"2024-04-05 11:13","pubTimestamp":1712286814,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，花旗发布研究报告称，维持锦欣生殖“买入”评级，考虑到深圳新院区延迟开业及武汉医院的利润，将2024及2025年收入下调10%和16.8%，每股盈测下调37.7%及40.9%，目标价由11.5港元下调至6港元。报告中称，锦欣生殖去年收入同比增18%至27.89亿元人民币，净利润升1.94倍至3.47亿元人民币，经调整净利润增72%至4.72亿元人民币，表现符合盈警预告。销售及行政支出比率降至24.1%；净利润率为12.4%。管理层给予指引2024财年的经调整净利润将同比升15%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1098795.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2425362309","title":"《大行报告》花旗削锦欣生殖(01951.HK)目标价至6元  业绩符合盈警预告","url":"https://stock-news.laohu8.com/highlight/detail?id=2425362309","media":"阿斯达克财经","top":-1,"share":"https://www.laohu8.com/m/news/2425362309?lang=zh_cn&edition=full","pubTime":"2024-04-05 10:18","pubTimestamp":1712283480,"startTime":"0","endTime":"0","summary":"花旗发表研究报告指，锦欣生殖去年收入按年增18%至27.89亿元人民币，净利润升1.94倍至3.47亿元人民币，经调整净利润增72%至4.72亿元人民币，表现符合盈警预告。销售及行政支出比率降至24.1%；净利润率为12.4%。该行表示，考虑到深圳新院区延迟开业及武汉医院的利润，将2024及2025年收入分别下调10%和16.8%，每股盈测分别下调37.7%及40.9%，目标价由11.5元下调至6元，维持“买入”评级。","market":"hk","thumbnail":"http://plib.aastocks.com/aafnnews/image/medialib/20201021150449928_s.jpg","type":0,"news_type":0,"thumbnails":["http://plib.aastocks.com/aafnnews/image/medialib/20201021150449928_s.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/analysis/china-hot-topic-content.aspx?id=NOW.1340244&catg=4&source=AAFN","is_publish_highlight":false,"gpt_icon":0},{"id":"2425700223","title":"锦欣生殖盘中异动 早盘大幅跳水5.33%报2.311港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2425700223","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2425700223?lang=zh_cn&edition=full","pubTime":"2024-04-05 09:52","pubTimestamp":1712281950,"startTime":"0","endTime":"0","summary":"2024年04月05日早盘09时52分，锦欣生殖股票出现波动，股价快速下挫5.33%。截至发稿，该股报2.311港元/股，成交量126万股，换手率0.05%，振幅6.15%。锦欣生殖股票所在的生物技术行业中，整体跌幅为1.34%。管理服务部门向锦江生殖中心及锦欣生育中心提供共同管理服务。消息层面，截至09时52分，锦欣生殖股票正面舆情新闻比例20%。《锦欣生殖2023年报点评：23年业绩符合预期 24年有望迎来复苏》资讯为影响锦欣生殖的重要信息。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404050952317a510c85&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404050952317a510c85&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2424868132","title":"锦欣生殖(1951.HK)2023年报点评：23年业绩符合预期 24年有望迎来复苏","url":"https://stock-news.laohu8.com/highlight/detail?id=2424868132","media":"光大证券","top":-1,"share":"https://www.laohu8.com/m/news/2424868132?lang=zh_cn&edition=full","pubTime":"2024-04-03 14:21","pubTimestamp":1712125316,"startTime":"0","endTime":"0","summary":"事件：公司公告23 年全年业绩，全年实现收入27.89 亿元，同比增长18.0%；实现净利润为3.47 亿元，同比增长194.2%；经调整净利润为4.72 亿元，同比增长72.0%；业绩符合预期。此外，公司积极拓展东南亚市场，近期公司与印尼最大辅助生殖集团Morula 达成战略合作，携手开拓印尼和东南亚市场，我们认为随着2024 年国际旅客的恢复，海外业务整体有望迎来恢复增长。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024040314215887d92d9e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024040314215887d92d9e&s=b","is_publish_highlight":false,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.jxr-fertility.com","stockEarnings":[{"period":"1week","weight":0.0783},{"period":"1month","weight":0.029},{"period":"3month","weight":0.004},{"period":"6month","weight":-0.3369},{"period":"1year","weight":-0.502},{"period":"ytd","weight":-0.2597}],"compareEarnings":[{"period":"1week","weight":0.0584},{"period":"1month","weight":0.0442},{"period":"3month","weight":0.061},{"period":"6month","weight":-0.0113},{"period":"1year","weight":-0.1232},{"period":"ytd","weight":0.009}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"锦欣生殖医疗集团有限公司是一家主要提供辅助生殖服务的中国公司。该公司通过三个业务部门开展业务。辅助生殖服务部门主要为患者提供两种治疗方案：人工受精（AI）及体外受精（IVF）技术。管理服务部门向锦江生殖中心及锦欣生育中心提供共同管理服务。辅助医疗服务部门主要通过深圳中山医院提供妇科、泌尿外科及内科等领域的医疗服务。该公司主要在中国和美国开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.4,"avgChangeRate":-0.091213},{"month":2,"riseRate":0.6,"avgChangeRate":0.044282},{"month":3,"riseRate":0,"avgChangeRate":-0.135709},{"month":4,"riseRate":0.6,"avgChangeRate":0.035357},{"month":5,"riseRate":0.75,"avgChangeRate":0.045756},{"month":6,"riseRate":0.75,"avgChangeRate":0.054109},{"month":7,"riseRate":0.4,"avgChangeRate":-0.057268},{"month":8,"riseRate":0.2,"avgChangeRate":-0.089717},{"month":9,"riseRate":0.2,"avgChangeRate":-0.054562},{"month":10,"riseRate":0.6,"avgChangeRate":0.048056},{"month":11,"riseRate":0.4,"avgChangeRate":0.153787},{"month":12,"riseRate":0.4,"avgChangeRate":-0.014286}],"exchange":"SEHK","name":"锦欣生殖","nameEN":"JXR"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"锦欣生殖(01951)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供锦欣生殖(01951)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"锦欣生殖,01951,锦欣生殖股票,锦欣生殖股票老虎,锦欣生殖股票老虎国际,锦欣生殖行情,锦欣生殖股票行情,锦欣生殖股价,锦欣生殖股市,锦欣生殖股票价格,锦欣生殖股票交易,锦欣生殖股票购买,锦欣生殖股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"锦欣生殖(01951)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供锦欣生殖(01951)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}